WESTPORT, CT / ACCESSWIRE / June 8, 2023 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct" or the "Company"), a company focused on developing life-enhancing breast healthcare products is delighted to announce its sponsorship of Camp Breastie 2023, organized by The Breasties, the groundbreaking nonprofit organization that fosters a sense of community for survivors, previvors, thrivers, and carevivors of breast cancer. As part of its commitment to supporting those affected by breast cancer, CYduct Diagnostics Inc. helped contribute to the success of the four-day summit, which took take place on June 1-4^th at Rock Hill, New York.

Camp Breastie is an unparalleled gathering that brings together hundreds of individuals who have been touched by breast and gynecologic cancer, whether as survivors, previvors (individuals with a higher risk of developing breast cancer due to genetic factors), thrivers (those currently living with stage 4), or carevivors (caregivers and loved ones). With a vision to create a supportive and empowering environment, The Breasties organized and conducted a dynamic program filled with engaging activities, educational sessions, and opportunities for networking and emotional support.

"We were thrilled to be a sponsor of Camp Breastie 2023," said Dom Gatto, Founder/CEO at CYduct Diagnostics Inc. "The Breasties' commitment to inclusivity and support aligns perfectly with our own mission to provide innovative diagnostics solutions for breast cancer. We believe in the power of community and are honored to contribute to an event that brings together individuals with a shared experience and empowers them to thrive."

CYduct Diagnostics Inc. has been at the forefront of advancements in medical diagnostics, particularly in the field of breast cancer assessment and detection. Their cutting-edge technologies and innovative approaches are revolutionizing the early detection and personalized approach to breast cancer, significantly improving patient outcomes. By sponsoring Camp Breastie, CYduct Diagnostics Inc. demonstrates its dedication to the breast cancer community beyond scientific breakthroughs, aiming to make a meaningful impact on the lives of individuals affected by the disease.

"We were incredibly honored to present at Camp Breastie 2023," stated CYduct Diagnostics' President/CMO Dr. Jill Dietz. "Our commitment to advancing breast cancer diagnostics aligns perfectly with Breasties vision to create a sense of belonging and empowerment for all individuals impacted by breast cancer. This partnership will enable us to contribute to an unforgettable experience for attendees, fostering connections and offering resources that will empower them in their personal journeys."

The Breasties, founded in 2018, has quickly gained recognition for its pioneering work in building a supportive community that transcends boundaries and embraces individuals at every stage of their breast cancer experience. Through events like Camp Breastie, they continue to make a difference in the lives of countless survivors, previvors, thrivers, and carevivors, ensuring that no one faces breast cancer alone. We encourage everyone to visit their official corporate site (https://thebreasties.org/) and social media accounts; https://www.facebook.com/thebreasties/ and https://www.instagram.com/the_breasties/.

We also encourage shareholders to visit our official corporate social media accounts as noted below for updates. Information on such platforms is not incorporated into this press release.

https://twitter.com/CYductDx
https://www.linkedin.com/company/cyductdx/
https://www.facebook.com/CYductDiagnostics

About CYduct Diagnostics, Inc.:

CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.

Additional information on its line of products will be available on the Company's website at: CYductDX.com.

FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION

This press release includes certain information that may constitute forward-looking statements. Forward-looking statements are typically identified by terminology such as "could," "may," "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "proposed," "planned," "potential" and similar expressions, or are those, which, by their nature, refer to future events. All statements, other than statements of historical fact, included herein, including statements about CYduct's beliefs and expectations, are forward-looking statements. Forward-looking information is necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Although CYduct believes that such statements are reasonable, it can give no assurance that such forward-looking information will prove to be accurate. CYduct cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors. Accordingly, due to the risks, uncertainties and assumptions inherent in forward-looking information, readers and prospective investors in the Company's securities should not place undue reliance on forward-looking information. All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof and is subject to change. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company assumes no obligation to revise or update forward-looking information to reflect new circumstances, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT:

CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112

SOURCE: CYduct Diagnostics, Inc